Tag Archives: severe aortic stenosis

La post-dilatación en el Valve in Valve presenta mejoría hemodinámica

Post-Dilation in Valve-in-Valve Implantation Offers Hemodynamic Improvement

Post-Dilation in Valve-in-Valve Implantation Offers Hemodynamic Improvement

Courtesy of Dr. Carlos Fava. A significant number of patients present severe aortic stenosis and undergo surgery with 19-to-21-mm bioprostheses. These patients frequently evolve with high gradients and receive Valve-in-Valve (ViV) implantation. In about a third of patients with high post-procedural gradient (≥20 mmHg), this has been associated with poor outcomes. This study analyzed 30 patients who underwent

TAVI-compressor

Bicuspid Valves Do Not Increase Mortality in TAVR

The frequency of bicuspid aortic valves (BcAV) are around 1%, but in 60+ patients it is associated to severe aortic stenosis. Even though surgery is the standard treatment, TAVR is the “off label” indication in high risk patients.   BcAV presents differences with tricuspids given that it is more elliptic, has asymmetric calcification and more

¿Qué pacientes con bajo flujo y bajo gradiente se benefician del recambio valvular?

Which Low-Flow, Low-Gradient Patients Benefit from Valve Replacement?

A mean gradient ≥40 mmHg, an aortic valve area ≤1 cm², or a combination of both, during dobutamine stress echocardiography, correctly qualifies as severe aortic stenosis in about half of all patients. The other half consists in cases of pseudo-severe aortic stenosis. In turn, a projected aortic valve area ≤1 cm² is a much better indicator than the

Remodelado miocárdico reverso luego del reemplazo valvular

Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As expected, this regression comes with structural and functional improvement that suggest it is a dynamic process. Fibrosis can be measured and quantified with cardiovascular MR, which makes it a potential therapeutic objective. Left ventricular hypertrophy is a key

La empresa líder en válvulas balón expandibles lanza también su válvula autoexpandible

Leading Manufacturer of Balloon-Expandable Valves Launches Self-Expanding Device

Edwards Lifesciences could have been satisfied after the success of the PARTNER trials and the improvements to its balloon-expandable valve (mainly as regards the delivery system profile and paravalvular leak reduction) in its last model, SAPIEN 3. However, it was not. The company decided to keep going, developing a valve that is radically different from its

Ventajas de la sedación consciente en el TAVI

The Perks of Conscious Sedation in TAVR

The main advantage of transcatheter aortic valve replacement (TAVR) has always been its less invasive nature, compared against surgery. Many of the advances in this technique revolve around making it even less invasive, increasing the gap between the two. The kind of anesthesia has been one of these many advances. There are several reports (in general from

Daño miocárdico ¿debemos comenzar a evaluarlo?

Cardiac Damage: Should we start to assess it?

Courtesy of Dr. Carlos Fava. The current recommendation for  aortic valve replacement is based on stenosis severity based on valvular criteria (mean transvalvular gradient, peak aortic velocity and valve index area) and the presence of symptoms, in addition to comorbidities, mainly for risk stratification. However, ventricular damage and/or its effect on cardiovascular hemodynamics are not regarded

Estenosis aórtica pura vs mixta en TAVI: beneficios y evolución

TAVR in Patients with Pure vs. Mixed Aortic Stenosis: Benefits and Evolution

Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has been proven to reduce mortality and improve the quality of life of patients with pure severe aortic stenosis (PAS). However, there is a significant number of patients who experience mixed aortic stenosis associated with moderate/severe aortic regurgitation (MAS). These subjects were excluded from the PARTNER

Enfermedad pulmonar y TAVI, solo se beneficia un grupo reducido de pacientes

Lung Disease and TAVR: Beneficial for a Reduced Group of Patients

Chronic Lung Disease often affects patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) or surgery. In fact, this is why patients with lung disease are often deemed inoperable and prescribed TAVR. This is the first time the benefit of TAVR has been assessed in this group of patients, for symptoms of these conditions can

Top